Diston joins Science Group as Science & Technology Director
11 July 2016: Science Group plc (AIM:SAG) today announces that it is to appoint Andrew Diston, of Medicom Innovation Partner and formerly of Cambridge Consultants Ltd, to the role of Group Science & Technology Director and a member of the Group Executive Board.
Andrew Diston is currently Executive VP at Medicom, where he has global responsibility for the commercial development of the Danish and Cambridge-based business. Medicom specializes in designing and developing advanced drug delivery and connected health systems. Prior to Medicom, he spent most of his career at Cambridge Consultants, ultimately as head of the medical technology design and development business. He will start work for Science Group in September and report directly to Martyn Ratcliffe, Chairman & CEO.
Science Group comprises four operating businesses, the original and largest being Sagentia, the Cambridge-based science and technology consulting business. Recent acquisitions by the Group have expanded operations into additional vertical markets providing new opportunities for growth. The role of Group Science & Technology Director engages the science, engineering and innovation capabilities of the operating businesses to open up new market opportunities whilst providing technology leadership across the Group.